Jointly Provided By

Activity Details

1 AMA PRA Category 1 Credit
1 ANCC contact hour
0.5 APRN contact hour
Released: October 12, 2017
Expires: October 12, 2018
1 hour to complete
No registration required



Target Audience

This activity has been designed to meet the educational needs of clinicians and registered nurses who manage patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach
  2. Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with rheumatoid arthritis
  3. Develop individualized treatment plans for patients with rheumatoid arthritis that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (bMARDs) based on safety and efficacy data
  4. Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  5. Integrate shared decision making and other patient education strategies for patients with rheumatoid arthritis

Activity Description

Rheumatoid arthritis (RA) is a chronic disease with devastating consequences if not optimally managed early in the disease process. To effectively treat RA, appropriate treatments need to be selected, disease and treatment outcomes must be measured regularly, and patients need to be engaged in their own care. These concepts underpin the treat-to-target (T2T) approach endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). The availability of several new treatments beyond conventional disease modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor (anti-TNF) inhibitors also increases the complexity of effective disease management.

This unique educational initiative harnesses the power of reflection and recognition of suboptimal approaches to patient management to allow you to rethink clinical decisions based on the scenarios presented and to modify management plans accordingly. You can compare your responses to interactive questions with those of your peers and learn from our expert faculty.


Jeffrey R. Curtis, MD, MS, MPH (Chair)
William J. Koopman Endowed Professor in Rheumatology and Immunology
Professor of Medicine, Division of Clinical Immunology and Rheumatology
Director, University of Alabama at Birmingham (UAB) Arthritis Clinical Intervention     Program
Co-Director, UAB Center for Education and Research on Therapeutics (CERTS) of Musculoskeletal Disorders
Co-Director, UAB Pharmacoepidemiology and Pharmacoeconomics (PEER) Unit
University of Alabama at Birmingham
Birmingham, AL

Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA

Peter C. Taylor, MA, BM, BCh, PhD, FRCP, FRCPE
Norman Collison Professor of Musculoskeletal Sciences
Fellow, St. Peter’s College
Head of Clinical Sciences, Biomedical Research Unit Inflammation Theme
Botnar Research Centre
University of Oxford
Oxford, England (UK)

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Jeffrey R. Curtis, MD, MS, MPH, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Genentech, Janssen, Lilly, Myriad, and Pfizer (Consulting Fees); and AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Genentech, Janssen, Lilly, Myriad, and Pfizer (Contracted Research).
  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Consulting Fees); AbbVie, Celgene, Novartis, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); Johnson & Johnson, Merck, and Pfizer (Ownership Interest).
  • Peter C. Taylor, MA, BM, BCh, PhD, FRCP, FRCPE, has affiliations with AbbVie, Biogen, Galapagos, GlaxoSmithKline, Janssen, Lilly, Pfizer, Sanofi, and UCB (Consulting Fees); and Abide Therapeutics, Celgene, Lilly, and UCB (Contracted Research).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests relative to the content to disclose.
  • Jessica Hatch has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.  This educational activity for 1 contact hour is provided by the Postgraduate Institute for Medicine. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™, 1 ANCC contact hour, and 0.5 APRN contact hours. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post test and evaluation will receive CME credit. You must score 75% or higher on the post test to receive credit for this activity. All other participants who successfully complete the post test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.